Bronchopulmonary Dysplasia and Chronic Lung Disease: Stem Cell Therapy

被引：12

作者：

Pierro, Maria ^{[1
,2
]}

Ciarmoli, Elena ^{[3
]}

Thebaud, Bernard ^{[4
,5
,6
]}

机构：

[1] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy

[2] IRCCS Ist Giannina Gaslini, Neonatal Intens Care Unit, I-16148 Genoa, Italy

[3] San Gerardo Hosp, MBBM Fdn, Neonatal Intens Care Unit, I-20900 Monza, Italy

[4] Childrens Hosp Eastern Ontario, Div Neonatol, Dept Pediat, Ottawa, ON K1H 8L1, Canada

[5] Ottawa Hosp, Res Inst, Regenerat Med Program, Sprott Ctr Stem Cell Res, Ottawa, ON K1H 8L6, Canada

[6] Univ Ottawa, Sinclair Inst Regenerat Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8L6, Canada

来源：

CLINICS IN PERINATOLOGY | 2015年 / 42卷 / 04期

关键词：

Bronchopulmonary dysplasia; Prematurity; Stem cells; Newborn; Clinical translation; UMBILICAL-CORD BLOOD; MESENCHYMAL STROMAL CELLS; BONE-MARROW; EXTREMELY PRETERM; ADIPOSE-TISSUE; ANIMAL-MODELS; LONG-TERM; INJURY; DIFFERENTIATION; TRANSPLANTATION;

D O I：

10.1016/j.clp.2015.08.013

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Bronchopulmonary dysplasia (BPD), a major complication of premature birth, still lacks safe and effective treatment. Mesenchymal stem cells (MSCs) have been proven to ameliorate critical aspects of the BPD pathogenesis. MSCs seem to exert therapeutic effects through the paracrine secretion of anti-inflammatory, antioxidant, antiapoptotic, trophic, and proangiogenic factors. Although these findings are promising, understanding the mechanism of action of MSCs and MSC manufacturing is still evolving. Several aspects can affect the efficacy of MSC therapy. Further research is required to optimize this potentially game-changing treatment but the translation of regenerative cell therapies for patients has begun.

引用

页码：889 / +

页数：23

共 75 条

[1] Autologous and allogeneic mesenchymal stem cells in organ transplantation: what do we know about their safety and efficacy? [J].